Palisade Bio, Inc. (NASDAQ:PALI – Free Report) – Stock analysts at Brookline Capital Markets raised their Q2 2026 earnings per share estimates for Palisade Bio in a report released on Wednesday, May 20th. Brookline Capital Markets analyst K. Raja now forecasts that the company will earn ($0.05) per share for the quarter, up from their previous estimate of ($0.06). The consensus estimate for Palisade Bio’s current full-year earnings is ($0.22) per share. Brookline Capital Markets also issued estimates for Palisade Bio’s Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.21) EPS, FY2028 earnings at ($0.25) EPS and FY2029 earnings at ($0.35) EPS.
Palisade Bio (NASDAQ:PALI – Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01).
Get Our Latest Stock Analysis on Palisade Bio
Palisade Bio Price Performance
NASDAQ:PALI opened at $2.01 on Friday. The firm has a market capitalization of $348.90 million, a P/E ratio of -1.99 and a beta of 1.52. The business has a 50 day simple moving average of $2.00 and a 200 day simple moving average of $1.92. Palisade Bio has a 12-month low of $0.53 and a 12-month high of $2.86.
Hedge Funds Weigh In On Palisade Bio
Several large investors have recently made changes to their positions in PALI. CTC Alternative Strategies Ltd. acquired a new position in shares of Palisade Bio in the 1st quarter worth approximately $31,000. Orbimed Advisors LLC lifted its stake in Palisade Bio by 24.7% during the first quarter. Orbimed Advisors LLC now owns 2,333,000 shares of the company’s stock valued at $4,083,000 after purchasing an additional 461,580 shares during the last quarter. Pale Fire Capital SE boosted its holdings in Palisade Bio by 57.6% during the first quarter. Pale Fire Capital SE now owns 111,410 shares of the company’s stock worth $195,000 after buying an additional 40,700 shares in the last quarter. Creek Drive Management Group LLC bought a new stake in Palisade Bio during the fourth quarter worth approximately $723,000. Finally, Seven Fleet Capital Management LP acquired a new position in Palisade Bio in the fourth quarter worth approximately $770,000. Institutional investors own 11.79% of the company’s stock.
Palisade Bio Company Profile
Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.
The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.
See Also
- Five stocks we like better than Palisade Bio
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
